Prostate Cancer

Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.

An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.

Providers are too cautious with testosterone therapy. The myth is that increasing testosterone level will cause prostate cancer. If you start with a myth, you have to disprove that myth with a trial that is probably too big to ever conduct and that nobody will ever fund. Although repeated studies have shown no risks with testosterone therapy, those small studies are never looked at.

A genome-wide association study of more than 80,000 men with prostate cancer identified nine new genetic risk factors for prostate cancer, including seven mainly or exclusively among men of African ancestry.

Use of active surveillance for low-risk and favorable intermediate-risk prostate cancer increased sharply in the United States during the past decade, according to data published in JAMA Internal Medicine.

Guidelines are urgently needed to ensure inclusion of men of African ancestry in genetic testing for advanced, early-onset and familial prostate cancers, according to research in Journal of the National Comprehensive Cancer Network.

A combination of enzalutamide and leuprolide significantly extended metastasis-free survival for men with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to a company press release.

In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the MMAI trial presented at ASCO Genitourinary Cancers Symposium.

A prostate cancer polygenic risk score did not better predict the risk for aggressive disease compared with a clinical risk predictor and may not be clinically useful, according to study results published in JAMA Internal Medicine.